CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...
Phase 3
Milano, Italy and 125 other locations
in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian...
Phase 2
Milan, Italy and 41 other locations
followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...
Phase 3
Milano, Italy and 213 other locations
the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...
Phase 2
Milano, Italy and 46 other locations
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....
Phase 3
Milano, Italy and 176 other locations
of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...
Phase 3
Milano, MI, Italy and 113 other locations
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...
Phase 3
Milan, Italy and 63 other locations
This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian...
Phase 2
Milan, Italy and 20 other locations
with either niraparib or lartesertib in participants with epithelial ovarian cancer. The participants will previously have progress...
Phase 2
Milano, Italy and 21 other locations
of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus* The study will ...
Phase 1, Phase 2
Milano, Italy and 49 other locations
Clinical trials
Research sites
Resources
Legal